Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA

Rice Hall James & Associates LLC purchased a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 578,118 shares of the company’s stock, valued at approximately $1,890,000. Rice Hall James & Associates LLC owned about 0.21% of Taysha Gene Therapies as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. ST Germain D J Co. Inc. lifted its position in shares of Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares during the last quarter. Marex Group plc acquired a new stake in Taysha Gene Therapies in the second quarter valued at $29,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth about $31,000. May Hill Capital LLC purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth about $37,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider directly owned 1,006,439 shares in the company, valued at $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Raymond James Financial began coverage on Taysha Gene Therapies in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 22nd. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Finally, Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Moderate Buy” and an average price target of $10.42.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $5.83 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The firm has a 50-day simple moving average of $4.85 and a 200-day simple moving average of $3.68. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -17.67 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.